BioCardia, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from BioCardia, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than almost all Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 704% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 88% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-1,011.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than almost all Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / -65%In 3 years sales changed by -100% while total assets changed by -65%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-16.8×Operating cash was negative last year, while some debt falls due within a year.
Lower than 51% of Healthcare companies in United States.
Cash Cushion Ratio
+14%Cash, after subtracting all debt, equals 14% of its market value (net cash).
Higher than 56% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
BioCardia, Inc. made a loss over the last year. BioCardia, Inc. owes $1.62 for every $1 it owns. BioCardia, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossBioCardia, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-13.19BioCardia, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$14 MThe total market value of all of BioCardia, Inc.'s shares at today's price (share price × number of shares), smaller than 84% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
NegativeBioCardia, Inc.'s net worth is negative ($1 M below zero, balance sheet 31 Mar 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Return on equity (ROE)
-1803.2%BioCardia, Inc. lost 1803.2% of its shareholders' money over the last year, lower than almost all Healthcare companies in United States.
Owes vs Owns
1.62×BioCardia, Inc. owes $1.62 for every $1 it owns, so it owes more than it owns, higher than 95% of Healthcare companies in United States.
Dividend yield
NoneBioCardia, Inc. does not currently pay a dividend.
Profit growth
LossBioCardia, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashBioCardia, Inc. held $2 M more cash than debt (net cash) at Dec 2025.
Questions
What is BioCardia, Inc.'s return on equity?
BioCardia, Inc. lost 1803.2% of its shareholders' money over the last year, lower than almost all Healthcare companies in United States.
How much does BioCardia, Inc. owe compared with what it owns?
BioCardia, Inc. owes $1.62 for every $1 it owns, so it owes more than it owns, higher than 95% of Healthcare companies in United States.
Does BioCardia, Inc. pay a dividend?
No. BioCardia, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.